相似文献
1
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
2
Assessment of the Activities of Ceftolozane/Tazobactam and Ceftazidime/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and Clinical Isolates at Montpellier University Hospital, France.
Microb Drug Resist. 2019 Nov;25(9):1325-1329. doi: 10.1089/mdr.2018.0439. Epub 2019 Jun 21.
3
Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2.
4
Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Clin Ther. 2016 Mar;38(3):431-44. doi: 10.1016/j.clinthera.2016.01.018. Epub 2016 Mar 2.
5
Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
Int J Antimicrob Agents. 2024 Jul;64(1):107186. doi: 10.1016/j.ijantimicag.2024.107186. Epub 2024 Apr 28.
6
Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0206721. doi: 10.1128/AAC.02067-21. Epub 2021 Dec 20.
7
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Int J Antimicrob Agents. 2015 Sep;46(3):266-71. doi: 10.1016/j.ijantimicag.2015.05.003. Epub 2015 Jun 14.
8
Antimicrobial Activity of Ceftolozane-Tazobactam, Ceftazidime-Avibactam, and Cefiderocol against Multidrug-Resistant Pseudomonas aeruginosa Recovered at a German University Hospital.
Microbiol Spectr. 2022 Oct 26;10(5):e0169722. doi: 10.1128/spectrum.01697-22. Epub 2022 Oct 3.
9
Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.00875-17. Print 2017 Oct.
10
The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.
J Antimicrob Chemother. 2017 Mar 1;72(3):762-769. doi: 10.1093/jac/dkw480.
引用本文的文献
1
ICU environment as a reservoir of KPC-ST307-Klebsiella pneumoniae high-risk clone resistant to ceftazidime-avibactam.
Sci Rep. 2025 Aug 12;15(1):29486. doi: 10.1038/s41598-025-14987-w.
2
In Vitro Activity of Novel β-Lactam/β-Lactamase Inhibitors Against Carbapenem-Resistant and in Korea.
Antibiotics (Basel). 2025 Jun 26;14(7):649. doi: 10.3390/antibiotics14070649.
3
Multi-Drug Resistant Gram-Negative Sepsis in Neonates: The Special Role of Ceftazidime/Avibactam and Ceftolozane/Tazobactam.
Medicines (Basel). 2025 Jun 26;12(3):17. doi: 10.3390/medicines12030017.
4
The Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem for Intra-abdominal Infections: A Systematic Review and Meta-Analysis.
Cureus. 2025 Jun 18;17(6):e86262. doi: 10.7759/cureus.86262. eCollection 2025 Jun.
5
A comparative analysis of clinical outcomes in hematological patients afflicted with bacteremia attributable to carbapenem-resistant versus .
Front Cell Infect Microbiol. 2025 Jun 17;15:1600746. doi: 10.3389/fcimb.2025.1600746. eCollection 2025.
6
Potential role of avibactam in restoring susceptibility in Escherichia coli with two copies of bla and PBP3 mutations.
Sci Rep. 2025 Jul 1;15(1):21161. doi: 10.1038/s41598-025-07624-z.
7
Evolution of ceftazidime-avibactam resistance driven by variation in to during treatment of ST11-K64 hypervirulent .
Front Cell Infect Microbiol. 2025 Jun 6;15:1607127. doi: 10.3389/fcimb.2025.1607127. eCollection 2025.
8
A high-resolution genomic and phenotypic analysis of resistance evolution of an strain from a critically unwell patient treated with piperacillin/tazobactam.
J Med Microbiol. 2025 May;74(5). doi: 10.1099/jmm.0.002018.
9
Antibiotic-Resistant : Current Challenges and Emerging Alternative Therapies.
Microorganisms. 2025 Apr 16;13(4):913. doi: 10.3390/microorganisms13040913.
10
Emergence and characterization of IncFII/IncR plasmids with multiple 5,692 bp- -bearing tandem repeats in ceftazidime/avibactam non-susceptible strains.
Front Microbiol. 2025 Apr 3;16:1534631. doi: 10.3389/fmicb.2025.1534631. eCollection 2025.
本文引用的文献
1
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8.
2
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2537-41. doi: 10.1128/AAC.03056-15. Print 2016 Apr.
3
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Int J Antimicrob Agents. 2015 Nov;46(5):502-10. doi: 10.1016/j.ijantimicag.2015.07.004. Epub 2015 Aug 10.
4
Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).
Diagn Microbiol Infect Dis. 2015 Dec;83(4):389-94. doi: 10.1016/j.diagmicrobio.2015.06.008. Epub 2015 Jun 17.
5
Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
Clin Ther. 2015 Jul 1;37(7):1564-71. doi: 10.1016/j.clinthera.2015.05.501. Epub 2015 Jun 15.
6
Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.
Int J Antimicrob Agents. 2015 Jul;46(1):53-9. doi: 10.1016/j.ijantimicag.2015.02.022. Epub 2015 Apr 14.
7
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
Lancet. 2015 May 16;385(9981):1949-56. doi: 10.1016/S0140-6736(14)62220-0. Epub 2015 Apr 27.
8
Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains.
Antimicrob Agents Chemother. 2015;59(6):3509-17. doi: 10.1128/AAC.00163-15. Epub 2015 Apr 6.
9
Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.
Antimicrob Agents Chemother. 2015;59(6):3656-9. doi: 10.1128/AAC.05024-14. Epub 2015 Apr 6.
10
In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitals.
Antimicrob Agents Chemother. 2015;59(6):3623-6. doi: 10.1128/AAC.00364-15. Epub 2015 Mar 30.
Zotero 插件